EQL Pharma AB (publ) EQL

Updated: 11 Jun 2026

NASDAQ | Biotech | Pharmaceuticals and niche generics

No signal published yet

We already track EQL Pharma and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow EQL Pharma free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Biotech
Sector
Pharmaceuticals and niche generics
We're already tracking EQL Pharma AB (publ) — here are the latest events we've registered

Recent News

  • On May 8, 2026, EQL Pharma released its year-end report for 2025/26, reporting record quarterly sales of SEK 120.2 million. However, earnings were impacted by one-off items and higher logistics costs driven by geopolitical tensions. The company also announced the recruitment of a new Chief Supply Chain Officer to strengthen its operations.

What Firelda Watch includes for EQL Pharma AB (publ)

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of EQL Pharma AB (publ) will be delivered in the same format.

Want to follow EQL Pharma AB (publ)? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow EQL Pharma free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

EQL Pharma AB (publ) EQL
EQL Pharma — follow and we'll monitor it
Follow EQL Pharma free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.